BioCentury
ARTICLE | Finance

Coronavirus could stall China IPOs

Bio-Thera raises $281M in STAR IPO but other biopharmas’ debuts in Hong Kong, Shanghai face delays

February 11, 2020 1:43 AM UTC
Updated on Mar 20, 2020 at 9:09 PM UTC

Although Bio-Thera priced its Shanghai IPO Monday, the Guangzhou-based antibody company will likely prove to be the exception among biotechs planning to debut on the Shanghai and Hong Kong exchanges as Asian markets remain volatile and 2019-nCoV-related travel restrictions scuttle plans for roadshows.

Qiming Ventures’ Nisa Leung told BioCentury she expects biotech listings in Hong Kong and mainland China to slow down. “I think it’s affecting everything right now,” she said, referring to the coronavirus...

BCIQ Company Profiles

Bio-Thera Solutions Ltd.